Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia

Journal of Oncology Pharmacy Practice

Volumn 5, Issue 1, 1999, Pages 22-31

  Fjornes, Tom ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Anemia; Chemotherapy; Erythropoiesis; Recombinant human erythropoietin; Renal insufficiency; Tumor

Indexed keywords

EID: 0037840101     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529900500102     Document Type: Review

References (62)

1. Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin Belg. 1996;51:36-52.
2. Means RT, Jr, Krantz SB. Progress in understanding the pathogenesis of anemia in chronic disease. Blood. 1992;80:1639-1647.
3. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med. 1989;111:992-1000.
4. Johannsen H, Jelkmann W, Wiedemann G, Otte M, Wagner T. Erythropoietin/hemoglobin relationship in leukaemia and ulcerative colitis. Eur J Haematol. 1989;43:201-206.
5. Jelkmann W, Wiedemann G. Serum erythropoietin level: relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow. Klin Wochenschr. 1990;68:403-407.
6. Jelkmann W, Fandrey J, Wiedemann G. Immunoreactive erythropoietin in the anemia of non-renal chronic diseases. Biomed Biochim Acta. 1990;49:265-270.
7. Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells. 1993;11:348-355.
8. Abels RJ. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol. 1992;87:4-11.
9. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med. 1990;322:1689-1692.
10. Wood PA, Hrushesky WJM. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95:1650-1659.
11. Bacha DM, Caparros-Sison B, Allen JA, Walker R, Tan CTC. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep. 1986;70:865-869.
12. Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, Siegel SE, Hammond GD. A phase II study of carboplatin in children with recurrent or progressive solid tumors. Cancer. 1994;73:1297-1301.
13. Van Glabbeke M, Renard J, Pinedo HM, et al. Iproplatin- and carboplatin-induced toxicities: overview of a phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG). Eur J Cancer Clin Oncol. 1988;24:255-262.
14. Blumberg N, Heal J, Chuang C, Murphy P, Agarwal M. Further evidence supporting a cause and effect relationship between blood transfusion and earlier cancer recurrence. Ann Surg. 1987; 207:410-415.
15. Gebbia V, Gebbia N, Testa A, et al. Subcutaneous recombinant human erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer. Int J Oncol. 1992;1:341-345.
16. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:378-381.
17. Kelley LL, Koury MJ, Bondurant MC, Koury ST, Sawyer ST, Wickrema A. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood. 1993;82:2340-2352.
18. Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 1992;84:98-103.
19. Oster W, Herrmann F, Cicco A, et al. Erythropoietin prevents chemotherapy-induced anemia: case report. Blut. 1990;60:88-92.
20. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991;9:2021-2026.
21. Bajetta E, Bartolomeo MD, Buzzoni R, Bochicchio AM, Colleoni M. Recombinant human erythropoietin (rHuEPO) in the treatment of anemia associated with solid tumors with or without marrow infiltration. Int J Oncol. 1993;3:1121-1126.
22. Cascinu S, Fedeli A, Fedeli L, Catalano G. Cisplatin-associated anaemia treated with subcutaneous erythropoietin: a pilot study. Br J Cancer. 1993;67:156-158.
23. Case DC, Bukowski R, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993;85:801-806.
24. Tsukuda M, Mochimatsu I, Nagahara T, et al. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunol Immunother. 1993;36: 52-56.
25. Cascinu S, Fedeli A, del Ferro E, Fedeli SL, Catalano G. Recombinant human erythropoietin treatment in cisplatinum-associated anemia: randomized, double-blind trial with placebo. J Clin Oncol. 1994;12:1058-1062.
26. Campos E, Radford J, Steward W, et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol. 1995; 13:1623-1631.
27. Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer. 1997;79:1623-1628.
28. Ludwig H, Fritz E, Leitgeb C, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 1993;4:161-167.
29. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 1994;73:2535-2542.
30. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. J Am Soc Hematol. 1994;84:997-1004.
31. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979; 63:1527-1531.
32. Kuzur ME, Greco FA. Cisplatin-induced anemia. N Engl J Med. 1980;303:110-110.
33. Rothmann S, Weick JK. Cisplatin toxicity for erythroid precursors. N Engl J Med. 1981;304:360-360.
34. Rothmann SA, Paul P, Weick JK, McIntyre WR, Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning. 1985;3:415-423.
35. Getaz EP, Beckley S, Fitzpatrick J, Dozier A. Cisplatin-induced hemolysis. N Engl J Med. 1980;302:334-335.
36. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH. Long-term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978;41:1274-1281.
37. Krakoff IH. Nephrotoxicity of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979;63:9-10.
38. Goldstein RS, Mayor GH. The nephrotoxicity of cisplatin. Life Sci. 1983;32:685-690.
39. Smith DH, Goldwasser E, Vokes E. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer. 1991;68:1101-1105.
40. Fjeldborg P, Soerensen J, Helkjaer E. The long-term effect of cisplatin on renal function. Cancer. 1986;58:2214-2217.
41. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 1977;39:1362-1371.
42. Ludwig H, Kotzman FE, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990;322:1693-1699.
43. Taylor J, Mactier RA, Stewart WK, Henderson IS. Effect of erythropoietin on anemia in patients with myeloma receiving hemodialysis. BMJ. 1990;301:476-477.
44. Oster W, Herrmann F, Gann H, et al. Erythropoietin for the treatment of anemia of malignancies associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990;8:956-962.
45. Gamucci T, Thorel MF, Frasca AM, Giannarelli D, Calabresi F. Antianemic activity of erythropoietin in cisplatin-treated patients: a randomized trial. Proc Am Soc Clin Oncol. 1992;11:1431-1431.
46. James RD, Wilkinson PM, Belli F, Welch R, Cowan R. Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results. Acta Haematol. 1992;87:12-15.
47. Cascinu S, del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology. 1995;52:422-426.
48. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer-associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995; 76:2319-2329.
49. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992;19:29-35.
50. Pawlicki M, Jassem J, Bösze P, et al. A multicenter study of recombinant human erythropoietin (epoietin a) in the management of anemia in cancer patients receiving chemotherapy. Anti-cancer Drugs. 1997;8:949-957.
51. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj, S. Impact of therapy with epoietin a on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
52. Markman M, Reichman B, Hakes T, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol. 1993;49:172-176.
53. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood. 1991;78:1658-1663.
54. Kasper C, Terhaar A, Fossaa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol. 1997;58:251-256.
55. Porter JC, Leahey A, Polise K, et al. Recombinant human erythro poietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr. 1996;129:656-660.
56. Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: results of a phase I/II clinical trial. Blood. 1992;79:29-37.
57. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056-1063.
58. Brod J. Prüfung der nierenfunktion. In Losse H, Renner E., eds. Klinische Nephrologie. Stuttgart, Germany: Thieme Verlag; 1982: 167-181.
59. Medenica R, Huschart T. Erythropoietin prevents anemia in chemotherapy cancer patients. Blood. 1990;76:154a-154a.
60. Fjornes T, Wiedemann GJ, Sack K, Jelkmann W. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anemic patients on chemotherapy. Oncol Rep. 1998;5:81-86.
61. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoietin-a) therapy in cancer patients. Blood. 1995;85:1676-1678.
62. Spivak JL. Serum immunoreactive erythropietin in health and disease. Int J Cell Cloning. 1990;8:211-226.